Arcus Biosciences Total Assets Growth & History (RCUS)
Arcus Biosciences's total assets was $1.14B for fiscal 2025.
View full Arcus Biosciences company overviewArcus Biosciences annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.14B | −$11.0M | −0.96% |
| 2024 | 2024-12-31 | $1.15B | $55.0M | +5.02% |
| 2023 | 2023-12-31 | $1.09B | −$250.0M | −18.59% |
| 2022 | 2022-12-31 | $1.34B | −$247.0M | −15.52% |
| 2021 | 2021-12-31 | $1.59B | $819.7M | +106.14% |
| 2020 | 2020-12-31 | $772.3M | $569.2M | +280.23% |
| 2019 | 2019-12-31 | $203.1M | −$71.8M | −26.12% |
| 2018 | 2018-12-31 | $274.9M | $84.4M | +44.33% |
| 2017 | 2017-12-31 | $190.5M | — | — |
Arcus Biosciences quarterly total assets
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $924.0M | −$151.0M | −14.05% |
| Q1 2026 | 2026-03-31 | $997.0M | −$159.0M | −13.75% |
| Q4 2025 | 2025-12-31 | $1.14B | −$11.0M | −0.96% |
| Q3 2025 | 2025-09-30 | $974.0M | −$278.0M | −22.20% |
| Q2 2025 | 2025-06-30 | $1.07B | −$111.0M | −9.36% |
| Q1 2025 | 2025-03-31 | $1.16B | −$137.0M | −10.60% |
| Q4 2024 | 2024-12-31 | $1.15B | $55.0M | +5.02% |
| Q3 2024 | 2024-09-30 | $1.25B | $61.0M | +5.12% |
| Q2 2024 | 2024-06-30 | $1.19B | −$34.0M | −2.79% |
| Q1 2024 | 2024-03-31 | $1.29B | $39.0M | +3.11% |
| Q4 2023 | 2023-12-31 | $1.09B | −$250.0M | −18.59% |
| Q3 2023 | 2023-09-30 | $1.19B | −$202.8M | −14.55% |
| Q2 2023 | 2023-06-30 | $1.22B | −$256.8M | −17.39% |
| Q1 2023 | 2023-03-31 | $1.25B | −$289.4M | −18.75% |
| Q4 2022 | 2022-12-31 | $1.34B | −$247.0M | −15.52% |
| Q3 2022 | 2022-09-30 | $1.39B | $554.5M | +66.07% |
| Q2 2022 | 2022-06-30 | $1.48B | $578.0M | +64.31% |
| Q1 2022 | 2022-03-31 | $1.54B | $608.3M | +65.05% |
| Q4 2021 | 2021-12-31 | $1.59B | $819.7M | +106.14% |
| Q3 2021 | 2021-09-30 | $839.3M | $28.2M | +3.48% |
| Q2 2021 | 2021-06-30 | $898.8M | $417.4M | +86.70% |
| Q1 2021 | 2021-03-31 | $935.1M | $759.0M | +430.88% |
| Q4 2020 | 2020-12-31 | $772.3M | $569.2M | +280.23% |
| Q3 2020 | 2020-09-30 | $811.1M | $594.1M | +273.84% |
| Q2 2020 | 2020-06-30 | $481.4M | $242.4M | +101.44% |
| Q1 2020 | 2020-03-31 | $176.1M | −$82.4M | −31.87% |
| Q4 2019 | 2019-12-31 | $203.1M | −$71.8M | −26.12% |
| Q3 2019 | 2019-09-30 | $217.0M | −$69.8M | −24.33% |
| Q2 2019 | 2019-06-30 | $239.0M | −$54.9M | −18.68% |
| Q1 2019 | 2019-03-31 | $258.5M | −$46.9M | −15.35% |
| Q4 2018 | 2018-12-31 | $274.9M | $84.4M | +44.33% |
| Q3 2018 | 2018-09-30 | $286.7M | — | — |
| Q2 2018 | 2018-06-30 | $293.9M | — | — |
| Q1 2018 | 2018-03-31 | $305.4M | — | — |
| Q4 2017 | 2017-12-31 | $190.5M | — | — |
Arcus Biosciences total assets trends
Over the last five fiscal years, Arcus Biosciences's total assets increased from $772.3M to $1.14B, a change of $366.7M. The latest reported quarter, Q2 2026, shows $924.0M.
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Arcus Biosciences source filings ↗